Ph II Data With Vertex' 141W94
Preliminary data from a Phase II, 12-week study of VertexPharmaceuticals' HIV protease inhibitor, 141W94 (VX 478), have shown that the drug, when used in combination with Glaxo Wellcome's nucleoside analogs Retrovir (zidovudine) and Epivir (lamivudine), suppresses viral load at below detectable levels in about 70% of patients.
Patients receiving triple therapy with the highest dose of 141W94 (1,200mg twice daily), saw a median reduction in viral load of more than 99.8% at study end. 141W94 is currently in Phase III clinical trials and is being developed by GW worldwide, except for the Far East where it is being developed by Kissei Pharmaceutical.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze